URGN - NASDAQ
UroGen Pharma Ltd.
$27.79
+4.7%UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
At a Glance
Live SnapshotUroGen Pharma Ltd. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
UroGen Pharma Ltd. Income Statement
URGN • NASDAQ
| UroGen Pharma Ltd. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||
109.8M | 90.4M | 82.7M | 64.4M | 48M | 11.8M | 18K | 1.1M | 8.2M | 17.5M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||||||
(12.4M) | (8.9M) | (9.4M) | (7.7M) | (5.2M) | (1M) | (0.0) | (1.8M) | (600K) | (28K) | (113K) | (0.0) | (0.0) | |
97.3M | 81.5M | 73.4M | 56.7M | 42.9M | 10.8M | 18K | -675K | 7.6M | 17.5M | -113K | 0.0 | 0.0 | |
OPERATING INCOME | |||||||||||||
(222.2M) | (178.3M) | (138.9M) | (135.7M) | (135.2M) | (137.5M) | (109.5M) | (76.5M) | (27.5M) | (16.7M) | (12.4M) | (4.4M) | (3.4M) | |
(155.1M) | (0.0) | (93.3M) | (82.8M) | (0.0) | (90.2M) | (60.2M) | (39.6M) | (8.8M) | (6.4M) | (1.9M) | (890K) | (1.1M) | |
(67.1M) | (57.1M) | (45.6M) | (52.9M) | (47.6M) | (47.3M) | (49.3M) | (36.9M) | (18.7M) | (10.3M) | (10.5M) | (4M) | (2.3M) | |
-124.9M | -96.8M | -65.5M | -79M | -92.3M | -126.7M | -109.5M | -77.2M | -20M | 798K | -12.4M | -4.4M | -3.4M | |
PRE-TAX INCOME | |||||||||||||
(33.8M) | (12.5M) | (14.7M) | (8.4M) | (0.0) | (357K) | (284K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-27.9M | -3.6M | -12.1M | -7.5M | 365K | 1.6M | 4.3M | 1.9M | 125K | 1K | 0.0 | 0.0 | 0.0 | |
(0.0) | (121.2M) | (0.0) | (0.0) | (87.5M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-28.6M | -27.3M | -32.8M | -29M | -17.1M | 1.6M | 4.3M | 1.6M | -31K | -2.7M | -279K | -107K | 83K | |
-153.4M | -124M | -98.3M | -108M | -109.4M | -125.1M | -105.1M | -75.5M | -20M | -1.9M | -12.7M | -4.5M | -3.3M | |
NET INCOME | |||||||||||||
(78K) | (2.8M) | (3.9M) | (1.8M) | (1.4M) | (3.4M) | (0.0) | (125K) | (19K) | (0.0) | (0.0) | (0.0) | (0.0) | |
-153.5M | -126.9M | -102.2M | -109.8M | -110.8M | -128.5M | -105.1M | -75.7M | -20M | -1.9M | -12.7M | -4.6M | -3.3M |
SEC Filings
URGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 02, 2026 | June 02, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | February 26, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 27, 2025 | August 26, 2025 | 2025 |
Related Guides
Continue your URGN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.